Scancell Holdings plc

OTCPK:SCNL.F Stock Report

Market Cap: US$205.0m

Scancell Holdings Valuation

Is SCNL.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of SCNL.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate SCNL.F's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate SCNL.F's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCNL.F?

Key metric: As SCNL.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SCNL.F. This is calculated by dividing SCNL.F's market cap by their current revenue.
What is SCNL.F's PS Ratio?
PS Ratio32.5x
SalesUK£4.71m
Market CapUK£153.07m

Price to Sales Ratio vs Peers

How does SCNL.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SCNL.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.2x
ANIK Anika Therapeutics
1.8x5.19%US$213.3m
KPTI Karyopharm Therapeutics
1.5x30.54%US$218.0m
DTIL Precision BioSciences
5.3x27.58%US$212.6m
QTTB Q32 Bio
4.3x38.30%US$218.1m
SCNL.F Scancell Holdings
32.5x-55.26%US$153.1m

Price-To-Sales vs Peers: SCNL.F is expensive based on its Price-To-Sales Ratio (32.5x) compared to the peer average (3x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does SCNL.F's PS Ratio compare vs other companies in the US Biotechs Industry?

111 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
3.1x2.53%US$30.78b
BMRN BioMarin Pharmaceutical
3.6x10.07%US$11.36b
BCRX BioCryst Pharmaceuticals
3.2x8.43%US$2.58b
SRPT Sarepta Therapeutics
1x-12.12%US$2.02b
SCNL.F 32.5xIndustry Avg. 12.2xNo. of Companies111PS01632486480+
111 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SCNL.F is expensive based on its Price-To-Sales Ratio (32.5x) compared to the US Biotechs industry average (11.7x).

Price to Sales Ratio vs Fair Ratio

What is SCNL.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCNL.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio32.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SCNL.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SCNL.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.42
0%
3.23%US$0.44US$0.41n/a2
Jul ’27US$0.28
US$0.42
+51.37%
3.23%US$0.44US$0.41n/a2
Jun ’27US$0.33
US$0.42
+26.07%
3.23%US$0.44US$0.41n/a2
May ’27US$0.17
US$0.42
+146.62%
3.23%US$0.43US$0.41n/a2
Apr ’27US$0.15
US$0.43
+193.92%
3.23%US$0.44US$0.41n/a2
Mar ’27US$0.20
US$0.43
+112.17%
3.23%US$0.44US$0.41n/a2
Feb ’27US$0.19
US$0.43
+125.24%
3.23%US$0.44US$0.41n/a2
Jan ’27n/a
US$0.41
0%
3.23%US$0.43US$0.40n/a2
Dec ’26n/a
US$0.42
0%
3.23%US$0.43US$0.40n/a2
Nov ’26US$0.12
US$0.42
+248.60%
3.23%US$0.43US$0.40n/a2
Oct ’26n/a
US$0.42
0%
3.23%US$0.43US$0.41n/a2
Sep ’26US$0.14
US$0.42
+196.64%
3.23%US$0.43US$0.41n/a2
Aug ’26US$0.14
US$0.39
+165.96%
12.28%US$0.43US$0.34n/a2
Jul ’26US$0.13
US$0.33
+156.56%
2.04%US$0.34US$0.33US$0.282
Jun ’26n/a
US$0.32
0%
2.04%US$0.32US$0.31US$0.332
May ’26US$0.17
US$0.32
+85.74%
2.04%US$0.32US$0.31US$0.172
Apr ’26n/a
US$0.33
0%
9.97%US$0.37US$0.30US$0.153
Mar ’26n/a
US$0.33
0%
9.97%US$0.37US$0.30US$0.203
Feb ’26n/a
US$0.33
0%
9.97%US$0.37US$0.30US$0.193
Jan ’26n/a
US$0.32
0%
15.42%US$0.39US$0.27n/a3
Dec ’25n/a
US$0.32
0%
15.42%US$0.39US$0.27n/a3
Nov ’25n/a
US$0.32
0%
15.42%US$0.39US$0.27US$0.123
Oct ’25n/a
US$0.32
0%
15.42%US$0.39US$0.27n/a3
Sep ’25n/a
US$0.32
0%
15.42%US$0.39US$0.27US$0.143
Aug ’25n/a
US$0.32
0%
15.42%US$0.39US$0.27US$0.143
Jul ’25n/a
US$0.31
0%
15.64%US$0.38US$0.27US$0.133
US$0.59
Fair Value
52.4% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/07 04:29
End of Day Share Price 2026/06/25 00:00
Earnings2025/10/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scancell Holdings plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julie SimmondsPanmure Liberum
James OrsborneStifel, Equities Research
Lala GregorekTrinity Delta Research Limited